MYO
Myomo, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Myomo, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report3 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
No changes.
No changes.
No thesis.
Largest filed tie
74.00%
of MYO revenue · Direct billing customers (patients/insurance)
Annual filing, covered
10-K parsed · Mar 9 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 9 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Myomo, Inc.
1.27
pre 1.29 +0.78%
Same SIC code · 6
Same SEC industry code: Intuitive Surgical Inc, Edwards Lifesciences Corp, Steris plc and 3 more; of Myomo, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Intuitive Surgical Inc, Edwards Lifesciences Corp, Steris plc and 3 more; of Myomo, Inc.'s 6 closest co-movers, none share that code.
+23.58%
vs ±59.1% implied · ×0.40
shaded = implied · ▲▼ = realized
Bull1
Bear1
| Manager | Value | % base | |
|---|---|---|---|
| Rosalind | $3.8M | 29.65% | −5.44% |
| Vanguardindex-like | $1.7M | 13.34% | +43.02% |
| AQR | $965,397 | 7.57% | +191.04% |
| Leucadia National | $732,446 | 5.74% | 0.00% |
| Jane Street | $708,606 | 5.55% | +6094.11% |
| Manager | Value | % base | |
|---|---|---|---|
| Rosalind | $3.8M | 29.65% | −5.44% |
| Vanguardindex-like | $1.7M | 13.34% | +43.02% |
| AQR | $965,397 | 7.57% | +191.04% |
| Leucadia National | $732,446 | 5.74% | 0.00% |
| Jane Street | $708,606 | 5.55% | +6094.11% |
Expected move
No implied move.